Shopping Cart
There are no more items in your cart
News
Next stop: The industry's top trade shows
Agarose Bead Technologies (ABT) is excited to announce our participation in several important trade fairs this October.
Read more
Agarose Bead Technologies expands facility to meet rising global demand for novel therapies market
Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.
Read moreSee you at Bioprocess International Conference and Exhibition 2024
ABT will be exhibiting at one of the most prestigious events in the bioprocessing industry, the Bioprocess International Conference. This prestigious event will be held...
Read more
Unveiling the role of TAOK3 and SHP-1 in T cell activation: Protein isolation and purification
Modulation of SHP-1 abundance by TAOK3 serves as a rheostat for TCR signaling and determines the activation threshold of T lymphocytes.
Read more
"This enhanced capacity will enable us to meet the evolving needs of the pharmaceutical industry, improve supply chain reliability, and reinforce our role as a trusted partner in the development of life-saving therapies."
Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.
Agarose Bead Technologies (ABT), a leading manufacturer of high-quality agarose resins, proudly announces the completion of a major expansion at its facility located in Northern Spain, Burgos.
The 1000 sqm addition positions ABT as one of Europe’s largest manufacturers of agarose resins, strategically advancing its ability to meet the growing global demand for agarose resins in the pharmaceutical and bioprocessing industry.
The Burgos site now boasts two new state-of-the-art cleanroom facilities and has increased its annual capacity to 100,000 liters of resins per year, enabling the firm to deliver larger-scale orders. More storage space will be available to accommodate large volumes of products and ensure a robust and reliable supply chain for customers.
The expansion comes as ABT solidifies its commitment to supporting the growing needs of biopharmaceutical companies engaged in the development of novel therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies.
As these therapies require advanced purification processes, the demand for high-quality agarose resins has surged, and ABT’s expanded capabilities aim to provide critical support to manufacturers worldwide.
“Our investment in expanding the Burgos facility is a direct response to the increasing global demand for high-quality agarose resins,” said Carolina Egea, CEO of Agarose Bead Technologies. “This enhanced capacity will enable us to meet the evolving needs of the pharmaceutical industry, improve supply chain reliability, and reinforce our role as a trusted partner in the development of life-saving therapies.”
Egea continued: “In line with ABT’s dedication to sustainability and environmental responsibility, the new facility incorporates energy-efficient systems and waste-reduction strategies. The company continues to prioritise compliance with rigorous industry standards, ensuring that its products meet the highest levels of purity and performance for biopharmaceutical applications.”
The expansion of the new facility was completed in June 2024 and is now fully operational.
Agarose Bead Technologies (ABT) is a leading European manufacturer of agarose resins supporting the Biopharmaceutical and Bioprocessing industry. Agarose resins are manufactured under a rigorous quality management system (QMS) needed to meet the requirements of the bioprocessing industry.